The class III histone deactylase (HDAC), SIRT1, has cancer relevance because it regulates lifespan in multiple organisms, down-regulates p53 function through deacetylation, and is linked to polycomb gene silencing in Drosophila. However, it has not been reported to mediate heterochromatin formation or heritable silencing for endogenous mammalian genes. Herein, we show that SIRT1 localizes to promoters of several aberrantly silenced tumor suppressor genes (TSGs) in which 5′ CpG islands are densely hypermethylated, but not to these same promoters in cell lines in which the promoters are not hypermethylated and the genes are expressed. Heretofore, only type I and II HDACs, through deactylation of lysines 9 and 14 of histone H3 (H3-K9 and H3-K14, respectively), had been tied to the above TSG silencing. However, inhibition of these enzymes alone fails to re-activate the genes unless DNA methylation is first inhibited. In contrast, inhibition of SIRT1 by pharmacologic, dominant negative, and siRNA (small interfering RNA)–mediated inhibition in breast and colon cancer cells causes increased H4-K16 and H3-K9 acetylation at endogenous promoters and gene re-expression despite full retention of promoter DNA hypermethylation. Furthermore, SIRT1 inhibition affects key phenotypic aspects of cancer cells. We thus have identified a new component of epigenetic TSG silencing that may potentially link some epigenetic changes associated with aging with those found in cancer, and provide new directions for therapeutically targeting these important genes for re-expression.
The propensity for cancer to arise and progress is influenced not only by gene mutations (genetic abnormalities), but also by defects in gene expression programs that are inherited from one dividing cell to another. This change in the inheritance of gene expression patterns not associated with changes in the primary DNA sequence is referred to as an epigenetic abnormality. In virtually every form of cancer, tumor suppressor genes (TSGs) and candidate TSGs are epigenetically altered such that the ability of these genes to become activated and lead to production of the corresponding proteins is lost. This so-called gene “silencing” is often linked with abnormal accumulation of methyl groups to DNA (DNA methylation) in a region of the gene that controls its expression. The SIRT1 protein is an enzyme that can remove acetyl groups attached to specific amino acids in a number of different protein targets and thereby regulate gene silencing in yeast. However, in mammalian cells this has not been demonstrated. Here, the authors show SIRT1 is involved in epigenetic silencing of DNA-hypermethylated TSGs in cancer cells. Inhibition of SIRT1 by multiple approaches leads to TSG re-expression and a block in tumor-causing networks of cell signaling that are activated by loss of the TSGs in a wide range of cancers. This finding has important ramifications for the biology of cancer in terms of what maintains abnormal gene silencing. Furthermore, the authors propose that their observations may have potential clinical relevance in suggesting new means for restoring expression of abnormally silenced genes in cancer.
Citation: Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang S-HL, Watkins DN, et al. (2006) Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation. PLoS Genet 2(3): e40. doi:10.1371/journal.pgen.0020040
Editor: Wolf Reik, The Babraham Institute, United Kingdom
Received: November 8, 2005; Accepted: February 6, 2006; Published: March 31, 2006
Copyright: © 2006 Pruitt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Our research was supported by a National Institutes of Health grant to SBB. KP is an American Cancer Society Postdoctoral Fellow.
Competing interests: SBB is a consultant to OncoMethylome Sciences. Under licensing agreement between the Johns Hopkins University and this company, MSP was licensed to OncoMethylome Sciences, and they are entitled to a share of the royalties received by the university from sales of the licensed technology.
Abbreviations: ChIP, chromatin immunoprecipitation; Ct, cycle threshold; HDAC, histone deactylase; HDI, histone deactylase inhibitor; MSP, methylation-specific PCR; NIA, nicotinamide; RNAi, RNA-interference; shRNA, short hairpin loop RNA; SPT, splitomicin; TSA, trichostatin-A; TSG, tumor suppressor gene
A growing list of tumor suppressor genes (TSGs) and candidate TSGs are epigenetically silenced in virtually every cancer type, and this silencing has been associated with aberrant promoter DNA methylation [1–3]. In previous studies, silencing of these genes was shown to involve dense hypermethylation of 5′ CpG islands and hypoacetylation of lysine 9 and 14 on histone H3 (H3-K9 and H3-K14, respectively) [4,5]. Moreover, synergistic reactivation of these TSGs can be achieved only when class I/II histone deactylase (HDAC) inhibitors (HDIs) are employed to treat tumor cells after DNA demethylating agents, such as 5-deoxy-azacytidine (DAC), have first induced at least partial promoter demethylation [5,6]. This suggested a dominance of the DNA methylation over H3-K9/K14 deactylation for maintenance of the gene silencing 
Another important class of HDACs, the NAD+-dependent sirtuins, or class III HDACs , has recently received much attention. The most prominent human family member, SIRT1 (Q96EB6), has only been shown to regulate transcriptional repression of mammalian target genes that are either already basally expressed  or to regulate transcriptional repression of an integrated Gal4-fusion reporter plasmid [9–11]. Thus far, SIRT1 has not been linked to heterochromatin maintenance or heritable silencing of TSGs, nor has it been well studied for endogenous mammalian genes. The sirtuins have distinct specific inhibitors [12–14] and are not responsive to drugs like trichostatin-A (TSA) or other class I and II HDIs previously used to study promoter-hypermethylated TSGs. At least eight different class I/II HDIs are advancing in different phases of clinical trials for cancer treatment [15,16], but inhibitors of sirtuin deacetylases have not been investigated for such use. The human class III HDAC, SIRT1, already has cancer relevance because it regulates gene silencing and/or lifespan in multiple organisms [17–20], regulates p53 function [21–23], and plays a critical role in stress signaling [24,25]. In addition, the yeast SIRT1 ortholog, Sir2, directly mediates histone-dependent gene silencing [7,26], and its counterpart in Drosophila has been linked to polycomb gene silencing . However, SIRT1 has not been demonstrated to mediate heritable silencing for endogenous mammalian genes.
To determine whether SIRT1 specifically plays a role in silencing TSGs whose promoters have 5′ CpG islands that are densely hypermethylated, we first applied screens using RNA-interference (RNAi) to disrupt the function of this protein and evaluate the effects on the targets. Both breast and colon cancer cell lines were chosen for our study, and several RNAi sequences targeting SIRT1 specifically were tested for their efficacy. SIRT1 protein levels in both MCF7 (Figure 1A) and MDA-MB-231 (Figure 1B) breast cancer cells were reduced via retroviral infection with a pSuper-retro-RNAi construct encoding short hairpin loop RNA (shRNA) specific for “knocking down” SIRT1. Three RNAi constructs were tested, and the sequence termed RNAi-3 yielded the greatest knockdown in MCF7 (Figure 1A), whereas both RNAi-2 and RNAi-3 were very effective in reducing protein levels in MDA-MB-231 cells (Figure 1B). Since we infected cells with equivalent titers of virus encoding the shRNAs, we are not sure why RNAi-3 was the most effective, but as shown below, the degree of knockdown served as a good control since it correlates very well with effects on gene re-expression.
(A) RNAi-3 is most effective for reduction of SIRT1 in MCF7 cells. Retroviral expression vectors encoding SIRT1 cDNA that produce short hairpin loop RNA targeting either distinct regions of SIRT1 mRNA (RNAi-1, −2, or −3) or a control (ctrl) were used to infect MCF7. Western blot analysis for SIRT1 and β-actin was performed 48 h after two rounds of infection.
(B) Both RNAi-2 and −3 are effective for reduction of SIRT1 protein in MDA-MB-231 cells as described in (A).
(C) SIRT1 inhibition leads to TSG re-expression in MCF7 cells. RNA was isolated from parallel samples analyzed in (A), and RT-PCR was performed with intron-spanning primers specific for the genes SFRP1 and SFRP2. GAPDH was also analyzed as a control. Only the shRNA (RNAi-3) that caused substantial reduction in SIRT1 protein leads to gene re-expression. Control samples in which no reverse transcriptase was added were analyzed separately, and all were negative for amplification of the indicated genes.
(D) SIRT1 inhibition leads to TSG re-expression in MDA-MB-231 cells. RT-PCR was performed for analysis of the genes SFRP1, SFRP2, and E-cadherin as described in (A). Only the shRNAs (RNAi-2 and −3) that caused substantial reduction in SIRT1 protein lead to gene re-expression
(E) SIRT1 inhibition leads to TSG re-expression in RKO cells. SIRT1 protein reduction by RNAi-3 (top panel) as described in (A) leads to gene re-expression of SFRP1, SFRP2, and MLH1 as described in (C)
(F) MDA-MB-231 and RKO cells infected with control or RNAi-3 shRNA as described in (A) were selected with puromycin for 3 d, and pooled colonies were harvested for Western blot analysis of protein re-expression that corresponded with the gene reactivation described in (D) and (E).
Strikingly, and correlating with the knockdown pattern of SIRT1 in each cell type, we observed re-expression of key TSGs that are frequently epigentically silenced in a number of different cancers. The anti-tumor genes identified all have promoter DNA hypermethylation, and they have important anti-tumor functions ranging from mediating proper epithelial cell differentiation to promoting cell–cell adhesion. The genes include members of the family of secreted frizzled-related proteins (SFRP1 and SFRP2), which are frequently epigenetically inactivated during colon and breast cancer progression, and contribute to aberrant activation of Wnt signaling (Figure 1C and 1D) [6,28]. Additionally, SIRT1 was found to maintain silencing of E-cadherin, a gene mediating cell–cell adhesion that is also inactivated epigenetically in many cancers (Figure 1D) [29–31]. Finally, SIRT1 protein levels were also reduced in RKO colon cancer cells and SIRT1was found to maintain silencing of TSGs including the mismatch repair gene, MLH1 (Figure 1E), for which epigenetic silencing and loss of function produces the microsatellite instability (MIN+) colon cancer phenotype [32,33] . Additionally, we found that the transcription factors encoding GATA-4 and GATA-5 genes, whose promoter DNA is hypermethylated , were also re-expressed in both colon and breast cancer cells (unpublished data).
To further determine whether the gene re-expression with this very specific approach for SIRT1 inhibition leads to protein re-expression, we performed parallel Western blots on samples for which proven antibodies are available. Consistent with gene re-expression, we found restoration of E-cadherin protein in breast and colon cancer cell lines and MLH1 in colon cancer lines in which these genes are hypermethylated and silenced (Figure 1F). These findings further demonstrate that SIRT1 specifically, and substantially, contributes to the aberrant heritable silencing of our panel of TSGs. Moreover, the levels of gene expression when SIRT1 function is reduced is similar to that observed for these genes when moderate doses of 5′-aza-deoxycytidine (Aza) is employed to achieve promoter demethylation [32,35]. Furthermore, we have demonstrated previously that the degree of protein re-expression for MLH1 obtained correlates with restored protein function in RKO cells .
To further assess the role SIRT1 plays in silencing TSGs whose promoter DNA is hypermethylated, we used two additional approaches. We applied a pharmacologic approach using the general sirtuin inhibitor, nicotinamide (NIA) [12,36], and the more sir2-specific inhibitor, splitomicin (SPT) [13,37]. Consistent with our above RNAi data, we found that these sirtuin inhibitors could cause the re-expression of the epigenetically silenced, hypermethylated TSGs studied above, and another such gene, CRBP1, in the human breast cancer cell lines MDA-MB-231 (Figure 2) or MCF7 (unpublished data). Using yet a third approach to assess the role that SIRT1 plays, we expressed a catalytically inactive, dominant negative inhibitor of SIRT1, SIRT1H363Y , and screened representative genes to further validate the specific involvement of this protein in repression of our panel of hypermethylated TSGs. In both MCF7 and MDA-MB-231 breast cancer cells in which SIRT1H363Y was expressed through retroviral infection, we observed a re-expression of SFRP1and SFRP2 (Figure 2E and 2F [left panel]). Additionally, we saw the same effect for GATA-4 in HCT116 colon cancer cells when the H363Y mutant was expressed, but not the wild type (unpublished data).
(A) Pharmacologic inhibition of SIRT1 causes TSG re-expression. MDA-MB-231 cells were treated with 15 mM NIA or 300 μM SPT for 21 h, RNA was isolated, and RT-PCR was performed with intron−spanning primers specific for the indicated genes. Control samples in which no reverse transcriptase was added were analyzed separately, and all were negative for amplification of the indicated genes.
(B) Combined treatment with low doses of Aza and SPT synergizes in the re-expression of TSGs. MDA-MB-231 cells were treated with either 50 nM Aza (+), 100 μM SPT (+) or with both Aza and SPT (++), and 34 h later, RT-PCR was performed for the indicated genes as described in (A).
(C) Combined treatment with SPT and TSA synergize in the re-expression of genes. MDA-MB-231 cells were treated with either 0, 50, 100, or 120 μM SPT alone for 34 h, or the treatment was followed by treatment with 300 nM TSA for 3 h prior to RNA isolation and RT-PCR analysis.
(D) SIRT1 protein knockdown synergizes with low doses of Aza for gene re-expression. MDA-MB-231 cells were infected with low titers of virus for shRNA specific for SIRT1. Aza (100 nM) was added 24 h prior to RNA isolation, and RT-PCR analysis was performed for the genes SFRP1, SFRP2, and GAPDH as described in (A).
(E) Dominant negative inhibition of SIRT1 leads to TSG re-expression in MCF7 cells. MCF7 cells were infected with virus encoding either pBabe (vec) or the catalytically inactive SIRT1H363Y (HY) mutant, and RT-PCR was performed as described in (A).
(F) Dominant negative inhibition of SIRT1 leads to TSG re-expression and synergizes with TSA and Aza. As shown in the left panel, MDA-MB-231 cells were infected with a control (vec) or mutant SIRT1 virus (HY), and RT-PCR was performed as described in (A). MDA-MB-231 cells were infected with low titers of pBabe or pBabe-SIRT1H363Y retrovirus and subsequently treated with 100 nM Aza for 24 h or with 300 nM TSA for 3 h prior to harvest, and RT-PCR was performed.
As discussed earlier, we have demonstrated previously that DNA methylation and histone deacetylation, involving class I and II HDACs, act as synergistic layers for TSG silencing in cancer and that inhibition of DNA methylation is dominant relative to the inhibition of deacetylation . Thus, we also wanted to determine whether disruption of sirtuin function could collaborate with either inhibitors of DNA methylation or class I/II HDIs in TSG re-expression. In this regard, low doses of Aza (50 nM) or SPT (50 μM) that were ineffective as single agents could be combined to achieve synergistic re-expression of our gene panel as shown by representative genes in Figure 2B.
Strikingly, we also found synergy in gene activation by combining the class I/II HDI, TSA, with increasing doses of SPT to reactivate genes whose promoters have hypermethylated DNA (Figure 2C and unpublished data). To again assess the synergy with DNA demethylation, we used low titers of shRNA retrovirus and low-dose Aza, and observed a synergistic re-expression of SFRP1 and SFRP2 (Figure 2D). The specific contribution of SIRT1 inhibition to the synergistic effects of combining either Aza treatment or TSA with sirtuin inhibition was investigated using low titers of SIRT1H363Y retrovirus. We also observed the synergistic reactivation of SFRP1 (Figure 2F, right panel), and GATA-5 and SFRP2 (unpublished data) in response to inhibition with the SIRT1 dominant negative SIRT1H363Y (HY) when used in low titers and combined with either Aza or TSA. These results provide strong evidence that, although SIRT1 inhibition alone is sufficient for the reactivation of our panel of TSGs, inhibition of DNA methylation and class I/II HDACs can cooperate with SIRT1 inhibition in such reactivation.
Given that SIRT1 appears to be intimately involved in maintaining silencing of the genes under study whose promoter DNA is densely hypermethylated, we wanted to determine whether the mechanism of reactivation coincided with any changes in the DNA methylation status at the re-expressed TSG promoters. To assess this, we performed extensive bisulfite sequencing of samples in which TSGs were reactivated by transient knockdown of SIRT1 by RNAi as shown in Figure 1 and by stable knockdown of SIRT1. Strikingly, we observed no change in promoter methylation of SFRP1 or GATA-5 (Figures 3A, S1, and S2). Moreover, a very sensitive, methylation-specific PCR (MSP) approach for detection of methylation status  yielded identical results (Figure 3B) to those from bisulfite sequencing. In all previous studies of these genes, a similar degree of reactivation with Aza is always accompanied by significant promoter demethylation as assessed by MSP analyses or bisulfite sequencing [28,34]. Furthermore, when the cells with stable RNAi knockdown were treated with NIA to further inhibit any remaining SIRT1 protein, as shown in the RNAi-2/NIA and RNAi-3/NIA lanes in Figure 3B, we observed no restoration to the unmethylated state for genes examined, even though they were re-expressed. Thus, it appears that SIRT1 inhibition alone is sufficient for the reactivation of tested TSGs even when dense promoter DNA methylation is maintained.
(A) TSG re-expression occurs without changes in the methylation profile of multiple clones analyzed for SFRP1 promoter methylation. Parallel samples analyzed in Figure 1D were subjected to bisulfite sequencing of the SFRP1 promoter from MDA-MB-231 cells stably infected with control vector or RNAi-2 or RNAi-3 retrovirus. Open circles indicate unmethylated cytosines, and closed circles indicate methylated cytosines. Numbers at the bottom show the position of cytosines relative to the transcription start site, which is at position 0, and those with a minus sign (−) are upstream from this start site. The region sequenced encompasses the CpG island in which methylation status correlates with gene expression status.
(B) MSP analyses of DNA from MDA-MB-231 cells stably expressing vector control, RNAi-2, or RNAi-3 retrovirus. From left to right: (-) PCR Ctrl indicates H2O only; (-) BS ctrl indicates bisulfite-treated H20; (+) M ctrl indicates the cell line in which SFRP1 is partially methylated and SFRP2 and GATA4 are fully methylated; and (+) U ctrl indicates the Tera-2 cell line in which each gene is unmethylated. All remaining lanes are for MDA-MB-231. From left to right: Aza indicates 1 μM Aza (24 h) treatment; Ctrl indicates empty vector infection; RNAi-2 indicates shRNA-2 infection alone; RNAi-3 indicates shRNA-3 infection alone; Aza indicates 1 μM Aza (24 h) treatment of control cells; Ctrl indicates empty vector infection + vehicle; RNAi-2 indicates shRNA-2 infection + 5 mM NIA treatment; and RNAi-3 indicates shRNA-3 infection + 5 mM NIA treatment.
One question that emerges with the above re-expression of genes induced by SIRT1 reduction in the face of retained DNA methylation is how the extent of transcription achieved compares to expression of these genes when DNA methylation alone is markedly reduced or absent. To examine this, we compared by RT-PCR (Figure 4A) and by quantitative real-time RT-PCR (Figure 4B) the re-expression achieved by SIRT1 knockdown of two genes with the basal expression of these same genes in an another cancer cell line in which the promoter DNA is not hypermethylated (Figure 4). In RKO cells in which SIRT1 protein levels were reduced via shRNA, and the residual SIRT1 protein was inhibited with SPT, we observed a restoration of CRBP1 and E-cadherin mRNA transcripts to about 60%–75% of the levels for their basal expression in HCT116 cells in which the promoter DNA is not hypermethylated. Similarly, levels of re-expression of the genes after SIRT1 reduction were comparable to those achieved after decreased DNA methylation using intermediate doses of Aza (500 nM) (Figure 4). These results provide evidence that SIRT1 inhibition plays a significant role in TSG re-expression even when promoter DNA methylation is retained and that SIRT1 likely cooperates with factors other than DNA methylation to help mediate the gene silencing.
(A) RKO cells were infected and stably selected to express short hairpin loop RNA targeting either a region unique to SIRT1 mRNA or a control (ctrl). To inhibit any residual SIRT1 protein, remaining RNAi-expressing cells were treated with 700 μM SPT and control samples were treated with DMSO for 24 h. For comparison, control RNA was isolated from parallel samples from HCT116 cells in which the two genes under study, CRB1 and E-cadherin, do not have promoter DNA hypermethylation and are basally expressed. RKO cells were also treated with 0.5 μM Aza (24 h), and samples were analyzed as described in Figure 1A; RT-PCR was performed with intron-spanning primers specific for the two genes. GAPDH was also analyzed as a control. Only the shRNA (RNAi-3) that caused substantial reduction in SIRT1 protein leads to gene re-expression. Control samples in which no reverse transcriptase was added were analyzed separately, and all were negative for amplification of the indicated genes.
(B) Parallel samples described above were analyzed using real-time quantitative PCR. The level of TSG re-expression induced by Aza treatment or SIRT1 inhibition as described in (A) was compared to levels of expression in HCT116 cells in which the TSGs are basally expressed.
How does SIRT1 function in contributing to the silencing of DNA hypermethylated TSGs? To address this question, we examined whether SIRT1 localizes to the promoters of the hypermethylated genes studied and directly modulates histone changes. We performed chromatin immunoprecipitation (ChIP) assays in MDA-MB-231 cells and observed SIRT1 localization at DNA-hypermethylated and silenced promoters for SFRP1, E-cadherin, and GATA-5 (Figure 5 and unpublished data) and at the silenced MLH1 and E-cadherin promoters in RKO colon cancer cells (Figure 5C). This localization was reduced with shRNA knockdown of SIRT1 (Figure 5A). Importantly, SIRT1 was absent from the promoters of the genes such as MLH1 and E-cadherin when their promoter DNA is not hypermethylated and the genes are basally expressed in the SW480 colon cancer cells (Figure 5C).
(A) Pooled populations of MDA-MB-231 cells stably selected to express RNAi constructs were analyzed via ChIP. These samples were isolated in parallel to those analyzed in Figure 3B. ChIP was performed with antibodies against SIRT1, acetylated histone H4, lysine 16 (H4-K16), or with no antibody (NAB) controls. Each promoter sequence was amplified by PCR under linear conditions for the genes SFRP1 and E-cadherin.
(B) The average change in SIRT1 localization, acetylation of H4-K16, and acetylation of H3K9 at the SFRP1 and E-cadherin promoters as measured by ChIP was quantitated for multiple experiments. Error bars indicate the standard deviation for multiple experiments.
(C) SIRT1 localizes to the promoters of silent genes whose DNA is hypermethylated, but not to these same promoters in cells in which the genes are expressed. ChIP was performed with antibodies against SIRT1 in RKO and SW480 colon cancer cells. As shown in the left panel, SIRT1 localizes to the MLH1 promoter in RKO cells in which the gene is silent, but not to the MLH1 promoter in SW480 cells in which it is expressed. As shown in the right panel, SIRT1 localizes to the E-cadherin promoter in RKO cells in which the gene is silent, but not to the E-cadherin promoter in SW480 cells where it is expressed.
We next determined how modifications of lysine residues known to be associated with transcriptional repression mapped with SIRT1-associated gene silencing. During SFRP1 reactivation, and concurrent with shRNA knockdown of SIRT1, we observed robust increases in acetylation of H4-K16 (Figure 5A and 5B) which has been documented as a direct target of SIR2 in yeast [39–41] and a preferential target in human cells for an introduced SIRT1 induction reporter system . Additionally, we observed significant increases in the levels of H4-K16 acetylation at the SFRP1, E-cadherin, and GATA-5 promoters (Figure 5A and 5B, and unpublished data). We observed modest increases in H3-K9 acetylation at the SFRP1 promoter and more substantial increases in H3-K9 acetylation at the E-cadherin promoter (Figure 4B). This latter modification has been tied to control by both class I and II HDACs, and SIRT1 [7,42].
Finally, from an overall cellular phenotype, we might predict that, if SIRT1 is involved in the repression of TSGs, inhibiting its function and concomitant re-expression of such genes should affect cell growth and/or viability. The numbers of DNA-hypermethylated and silenced TSGs in the cancer cell lines under examination make a direct analysis of this difficult. However, we tested the effects of SIRT1 on a series of colon and breast cancer phenotypic characteristics that would be predicted to change dramatically with re-expression of the TSGs under study. First, we examined the numbers of drug-resistant colonies that are formed during drug selection of cells for stable siRNA (small interfering RNA) knockdown of SIRT1. As shown in Figure 6A, we observed a sharp reduction in cell colonies during such selection.
(A) MDA-MB-231 cells were infected for two rounds with RNAi-2 and −3 retrovirus, and puromycin-resistant colonies were counted after 3 d of selection. Error bars indicate standard deviation from the average of three experiments.
(B) RKO cells were transfected with 500 ng of pGL3-OT, a TCF-LEF−responsive reporter, or pGL3-OF, a negative control with a mutated TCF-LEF binding site in combination with 10 ng of pRL-CMV vector. Twenty-four hours post-transfection, cells were treated with either vehicle (DMSO) control or with 700 μM SPT for 24 h. Firefly luciferase activity was measured and normalized to the Renilla luciferase activities.
(C) As described in (A), pooled populations of MDA-MB-231 cells stably expressing RNAi-2 or RNAi-3 were harvested, protein concentrations were determined, and Western blot analysis was performed. An antibody that specifically recognizes the unphosphorylated (active) form of β-catenin was used, and on the same blot, β-actin was probed to ensure equal loading.
(D) Western blot analysis was performed on RKO cells expressing control or SIRT1 RNAi. Antibodies against SIRT1, phospho-GSK3β (inactive), cyclin D1, p27, and β-actin were used for Western blotting. On the same blot, β-actin was probed to ensure equal loading.
Although the re-expression of many genes could account for the type of phenotypic change shown above, we queried whether reactivation of SFRP genes might be involved. We have shown previously that the silencing of the SFRP1 and -2 genes is important for aberrant activation of the Wnt pathway in colon cancer cells, and their re-introduction into such cells in which the genes are silenced causes sharp down-regulation of Wnt pathway function and apoptosis. . First, we tested for the possible impact of the re-expression of these genes in colon cancer cells by examining key parameters of the Wnt signaling pathway following SIRT1 inhibition. We found a 50% reduction in the activation of a β-catenin–responsive TCF reporter construct, a canonical readout for Wnt pathway activity in colon cancer cells [28,43,44] with SPT treatment of RKO colon cancer cells (Figure 5B). Additionally, we found a 50% reduction in the activation of a β-catenin–responsive cyclin-D1 promoter reporter construct [45,46] with SPT treatment of RKO cells (data not shown). We also observed suppression of other Wnt pathway signaling parameters in that there was a decrease in inactive phospho-GSK-3β, a member of the β-catenin destruction complex, and a reduction in cyclin D1 levels, a downstream target of nuclear β-catenin (Figure 6). We further observed that inhibition of SIRT1 lead to increases in p27 protein levels in RKO cells, an observation consistent with another report  using dominant negative inhibition of SIRT1 in another cell type. As demonstrated in Figures 1 and 2 in breast cancer cells, SIRT1 is involved in the silencing of SFRP1 and −2. Moreover, MDA-MB-231 cells express the wnt7b oncogene . In MDA-MB-231 cells in which SIRT1 was inhibited stably by RNAi, we observed a sharp reduction in the levels of unphosphorylated or active β-catenin (Figure 5B). Thus, SIRT1 inhibition causes re-expression of SFRPs that antagonize WNT signaling. Furthermore, SIRT1 inhibition causes re-expression of the E-cadherin gene, whose protein product complexes with β-catenin, and this gene reactivation collectively may suppress the constitutive activation of the WNT signaling pathway.
Our findings for a prominent role for SIRT1 in epigenetic silencing of genes whose promoters are hypermethylated in cancer cells has important ramifications for the biology of cancer. Multiple actions now attributed to SIRT1 indicate that this protein could have important oncogenic roles. The effects of knocking down SIRT1 levels on cancer cell phenotypic features as found in our present study attest to this. The mechanisms by which SIRT1 could serve as an oncogene are multifactorial. First, there are data suggesting high expression of this protein in a number of cancer cell lines [49,50], and we have observed this as well (unpublished data and ). Second, SIRT1 deacetylates several transcription factors that could potentially compromise TSG function, such as for p53 [21–23]. Third, single-copy increases in SIRT1 orthologs in multiple organisms or application of sirtuin activators have been shown to prolong cellular lifespan [7,52]. Although this may obviously have beneficial effects in multiple cell settings, such prolongation may have a damaging effect from the standpoint of selecting for neoplastic cells during tumor progression.
We now provide another mechanism through which SIRT1 might prolong survival of cells at risk for transformation by participating in abnormal epigenetic silencing of TSGs. One possible scenario that ties this role of SIRT1 to a cascade of epigenetic events observed in cancer comes from our recent observation that HIC1, a gene that is frequently epigenetically silenced early in tumorigenesis, can be localized to the SIRT1 promoter. Thus, in Hic1-null MEFs (mouse embryonic fibroblasts), there is a corresponding increase in SIRT1 levels . Our current results indicate that the role of increased levels of SIRT1 in the silencing of additional TSGs could also contribute to its oncogenic potential and suggests a series of epigenetic feedback events that would all predispose cells to aberrant gene silencing. We tested the effects of SIRT1 on a series of colon and breast cancer phenotypic characteristics that would be predicted to change dramatically with re-expression of the TSGs under study. We observed a reduction in the numbers of drug-resistant colonies that are formed during drug selection of cells for stable siRNA knockdown of SIRT1. Although we observed a sharp reduction in cell colonies during such selection, we acknowledge that there is no way to know to what degree this effect is solely mediated by the role of SIRT1 in the gene silencing studied in our current work and/or how this would co-operate with other SIRT1-mediated events. However, this result is consistent with another report demonstrating that SIRT1 reduction via RNAi induces either growth arrest or apoptosis in human epithelial cancer cells and suggests an oncogenic role for increased levels of this protein in cancer cells .
Another important possibility from our findings also relates to the role of SIRT1 in lifespan prolongation and delay of aging effects. The process of aging has been tightly linked to increasing promoter DNA hypermethylation in cancer-prone sites such as the human colon . Certainly it will now be important to study further whether this aging response may involve related increases in SIRT1 levels that may, in turn, facilitate aberrant gene silencing. From our observations it is clear that SIRT1 is necessary for maintaining aberrant silencing of TSGs, but the question still remains whether its increased expression is sufficient for the initiation of TSG silencing.
The mechanism through which SIRT1 participates in the gene silencing accompanying DNA hypermethylation of TSGs is also important to understand. Our present data indicate that the protein plays its role by localizing to the promoters of such silenced genes and deacetylating key histone lysine residues that are known to be critical for transcriptional repression. The targeting events for this recruitment will additionally be important to understand. Interestingly, the recent report that cancer cells have increased overall levels of deacetylation of the known histone target of SIRT1, H4-K16 , could well be related to the findings we now report at localized regions of aberrantly silenced TSGs. The role of SIRT1 at other silenced genes, including those in normal cells is not known. Considering the observations described here, an important focus of future work should involve testing whether SIRT1 associates with those few DNA-methylated genes in normal settings that contain promoter CpG islands, such as those on the inactive X chromosome of females or silenced alleles of imprinted genes.
Finally, our findings have potential clinical relevance. Combination therapies involving DNA-demethylating agents and class I/II HDAC inhibitors are receiving much attention for their potential therapeutic use in restoring expression of abnormally silenced genes in cancer [15,16]. Targeting SIRT1 in these strategies may be especially important. We have shown that blocking SIRT1 function synergizes with both promoter demethylation and inhibition of class I and II HDACs for gene reactivation and associated chromatin modification changes. Moreover, this inhibition of SIRT1 leads to gene reactivation even with retention of DNA methylation. Our findings then suggest new directions for targeting reversal of abnormal gene silencing and demonstrate the importance of continued study, which may lead to the eventual translation into the clinic.
Materials and Methods
Cell culture and retroviral infection.
MDA-MB-231, MCF7, HCT116, SW480 RKO, and Phoenix cells (ATCC, Rockville, Maryland, United States) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, Carlsbad, California, United States). Retroviral infection was performed using either single or multiple rounds of infection. Briefly, Phoenix cells were transfected with either pBabe, pBabe-SIRT1H363Y, pSUPERretro, pSUPERretro-SIRT1-RNAi-1–3 (NM_012238 positions 410, 589, and 1091; Oligo Engine, Seattle, Washington, United States) using Lipofectamine 2000 (Invitrogen). After 48 h of transfection, the medium containing retrovirus was collected, filtered, and supplemented with Polybrene prior to infection of target cells (MDA-MB-231, MCF7, or HCT116). Infected cells were either harvested 24–48 h later or subjected to selection with 2–3 μg/ml puromycin for a week prior to harvest and analysis.
RNA and protein preparation and analysis.
Total RNA was extracted (Invitrogen) according to the manufacturer's instructions and subjected to reverse transcription followed by both quantitative real-time and semi-quantitative polymerase chain reaction. For quantitative real-time analyses, the QuantiTect SYBR Green PCR kit (Qiagen, Valencia, California, United States) was used and the amplification conditions consisted of an initial 10-min denaturation step at 95 °C, followed by 40 cycles of denaturation at 95 °C for 15 s and annealing and extension for 30 s and 60 s, respectively. A BioRad iCycler was used (BioRad, Hercules, California, United States), and for quantitation the comparative cycle threshold (Ct) method was used, normalizing the Ct values for the indicated gene to the Ct values of GAPDH relative to a control sample. For conventional PCR, at least two independent sets of intron-spanning primers [28,34,56] were used for the analysis of multiple genes, such as CRBP1, (NM_002899), E-cadherin, (L34545), SFRP1, (BC036503), SFRP2, (BC008666), and Gata-4 (L34357). For Western blots, cells stably expressing RNAi constructs were harvested in 50 mM Tris-HCl, 1% NP-40, .25% sodium deoxycholate, 150 mM NaCl, 50 mM sodium fluoride, 1 mM dithiothreitol, 1 mM AEBSF, 1× Complete protease inhibitor cocktail (Roche, Basel, Switzerland). Protein concentrations were measured by BCA (Pierce Biotechnology, Rockford, Illinois, United States). Protein extracts were subjected to polyacrylamide gel electrophoresis using the 4%–12% NuPAGE gel system (Invitrogen), transferred to PVDF (Millipore, Billerica, Massachusetts, United States) membranes, and immunoblotted using antibodies that specifically recognize SIRT1 (DB083; Delta Biolabs, Gilroy, California, United States, and 05–707; Upstate, Charlottesville, Virginia, United States), E-cadherin (Transduction Laboratories 610182; BD Biosciences, San Diego, California, United States), hMLH1 (551091; BD Biosciences), cyclin D1 (556470; BD Biosciences), p27Kip1 (Transduction Laboratories K25020; BD Biosciences), the unphosphorylated (active) form of β-catenin (05–665; Upstate), and phospho-GSK3β (05–643; Upstate). On the same blot, β-actin (Sigma, St. Louis, Missouri, United States) was probed to ensure equal loading.
Reporter assays were performed as described previously using the b-catenin–responsive TCF reporter  and the cyclin D1 reporter. Briefly, prior to transfection, RKO cells were plated in six-well tissue culture dishes and grown until they reached 80%–90% confluence. Cells were transfected with 500 ng of pGL3-OT, a TCF-LEF−responsive reporter, or pGL3-OF, a negative control with a mutated TCF-LEF binding site in combination with 10 ng of pRL-CMV vector. Twenty-four hours post-transfection, cells were treated with either vehicle (DMSO) control or with 700 μM SPT for 24 h. According to the manufacturer's instructions, Firefly luciferase activity was measured via a luminometer (BD Biosciences) and normalized to the Renilla luciferase activities by using the Dual Luciferase Reporter System (Promega, Madison, Wisconsin, United States).
ChIP analysis was performed as previously described  with a few modifications. Antibodies to SIRT1 (05–707 and 07–313), acetyl-sH3-K9 (07–352), and acetyl-H4-K16 (07–329) were obtained from Upstate. Antibodies to SIRT1 were also obtained from Delta Biolabs (DB083). Primers (Forward: AGCCGCGTCTGGTTCTAGT; Reverse: GGAGGCTGCAGGGCTG) were designed for the SFRP1 promoter spanning −163 to +12 relative to the transcription start site (+1) and were amplified by PCR under linear conditions. Enrichment was calculated as the ratio between the net intensity of the bound SFRP1 sample divided by the input and the vector control sample divided by the input. Primers for E-cadherin were (Forward: TAGAGGGTCACCGCGTCTATG) and (Reverse: GGGTGCGTGGCTGCAGCCAGG), which encompass a CAAT signal.
MSP and bisulfite sequencing.
Figure S1. SIRT1 Inhibition Causes TSG Re-Expression without Changing SFRP1 Promoter DNA Hypermethylation
Bisulfite sequencing was performed on the SFRP1 promoter from MDA-MB-231 cells stably infected with control vector or RNAi-3 retrovirus as described in Figure 3. Open circles indicate unmethylated cytosines and closed circles indicate methylated cytosines. Numbers at the bottom show position of cytosines relative to the transcription start site, which is at position 0, and those with a minus sign (−) are upstream from this start site. The region sequenced encompasses the CpG island in which methylation status correlates with gene expression status.
(2.0 MB EPS)
Figure S2. SIRT1 Inhibition Causes TSG Re-Expression without Changing GATA-5 Promoter DNA Hypermethylation
Bisulfite sequencing was performed on the GATA-5 promoter from MDA-MB-231 cells stably infected with control vector or RNAi-3 retrovirus as described in Figure 3. The region sequenced has previously been shown to be the region in which methylation occurs that most closely correlates with transcriptional activity. Open circles indicate unmethylated cytosines, and closed circles indicate methylated cytosines. Numbers at the bottom show position of cytosines relative to the transcription start site, which is at position 0, and those with a minus sign (−) are upstream from this start site. The region sequenced encompasses the CpG island in which methylation status correlates with gene expression status.
(1.5 MB EPS)
The National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov) accession numbers for the genes and gene products discussed in this paper are CRBP1 (GeneID: 5947), cyclin-D1 (GeneID: 595), E-cadherin (GeneID: 999), GATA-5 (GeneID: 140628), MLH1 (GeneID: 4292), SFRP1 (GeneID: 6422), and SFRP2 (GeneID: 6423). The accession numbers for the proteins discussed in this paper are β-catenin (P35222), cyclin D1 (P24385), phospho-GSK-3β (P49841), and Sir2 (P53685).
KP and SBB conceived and designed the experiments. KP, RLZ, JEO, KMM, and SHLK performed the experiments. KP, RLZ, KMM, DNW, JGH, and SBB analyzed the data. KP, JGH, and SBB contributed reagents/materials and wrote the paper.
- 1. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042–2054.
- 2. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428.
- 3. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21: 163–167.
- 4. Fahrner JA, Eguchi S, Herman JG, Baylin SB (2002) Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62: 7213–7218.
- 5. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103–107.
- 6. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141–149.
- 7. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417–435.
- 8. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771–776.
- 9. Senawong T, Peterson VJ, Leid M (2005) BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch Biochem Biophys 434: 316–325.
- 10. Senawong T, Peterson VJ, Avram D, Shepherd DM, Frye RA, et al. (2003) Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression. J Biol Chem 278: 43041–43050.
- 11. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, et al. (2004) Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 16: 93–105.
- 12. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA (2002) Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277: 45099–45107.
- 13. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA (2001) Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A 98: 15113–15118.
- 14. Avalos JL, Bever KM, Wolberger C (2005) Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 17: 855–868.
- 15. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923–3931.
- 16. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, et al. (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495–528.
- 17. Olaharski AJ, Rine J, Marshall BL, Babiarz J, Zhang L, et al. (2005) The favoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet 1: e77.. DOI: 10.1371/journal.pgen.0010077.
- 18. Guarente L (2000) Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 14: 1021–1026.
- 19. Guarente L, Kenyon C (2000) Genetic pathways that regulate ageing in model organisms. Nature 408: 255–262.
- 20. Nemoto S, Fergusson MM, Finkel T (2004) Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105–2108.
- 21. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159.
- 22. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137–148.
- 23. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, et al. (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383–2396.
- 24. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011–2015.
- 25. Giannakou ME, Partridge L (2004) The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 14: 408–412.
- 26. Gottschling DE (2000) Gene silencing: Two faces of SIR2. Curr Biol 10: R708–R711.
- 27. Furuyama T, Banerjee R, Breen TR, Harte PJ (2004) SIR2 is required for polycomb silencing and is associated with an E(Z) histone methyltransferase complex. Curr Biol 14: 1812–1821.
- 28. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417–422.
- 29. Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, ey al. (2001) Frequent hypermethylation of the 5′ CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 7: 2765–2769.
- 30. Strathdee G (2002) Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 12: 373–379.
- 31. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, et al. (2000) E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res 6: 4243–4248.
- 32. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95: 6870–6875.
- 33. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, et al. (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57: 808–811.
- 34. Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, et al. (2003) GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 23: 8429–8439.
- 35. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG (2000) Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275: 2727–2732.
- 36. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA (2003) Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423: 181–185.
- 37. Posakony J, Hirao M, Stevens S, Simon JA, Bedalov A (2004) Inhibitors of Sir2: Evaluation of splitomicin analogues. J Med Chem 47: 2635–2644.
- 38. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821–9826.
- 39. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795–800.
- 40. Suka N, Luo K, Grunstein M (2002) Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet 32: 378–383.
- 41. Kimura A, Umehara T, Horikoshi M (2002) Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing. Nat Genet 32: 370–377.
- 42. Shankaranarayana GD, Motamedi MR, Moazed D, Grewal SI (2003) Sir2 regulates histone H3 lysine 9 methylation and heterochromatin assembly in fission yeast. Curr Biol 13: 1240–1246.
- 43. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 275: 1784–1787.
- 44. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787–1790.
- 45. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422–426.
- 46. Pruitt K, Pestell RG, Der CJ (2000) Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells. J Biol Chem 275: 40916–40924.
- 47. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551–563.
- 48. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL (1994) Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 54: 2615–2621.
- 49. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369–2380.
- 50. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, et al. (2005) Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A 102: 1859–1864.
- 51. Chen WY, Wang DH, Yen RC, Luo J, Gu W, et al. (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437–448.
- 52. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686–689.
- 53. Ford J, Jiang M, Milner J (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457–10463.
- 54. Toyota M, Issa JP (1999) CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9: 349–357.
- 55. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400.
- 56. Esteller M, Guo M, Moreno V, Peinado MA, Capella G, et al. (2002) Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 62: 5902–5905.